Business Context and Reporting Period
Company: Vyome Holdings, Inc. (Ticker: HIND)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2026
Business Overview: Vyome is a clinical-stage specialty pharmaceutical company focused on immune-inflammatory and rare diseases. The company operates two segments: Biotechnology (development of drug candidates like VT-1953 for malignant fungating wounds and VB-1953 for acne) and Pharmaceutical (commercialized anti-fungal products in India via a partnership with Sun Pharma).
Recent Corporate Action: The company completed a reverse merger with Reshape Lifesciences, Inc. in August 2025, becoming a Nasdaq-listed entity. A 5,000:1 reverse stock split was effected in August 2025.
Key Financial Metrics
| Metric (USD) | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $31,591 | $198,581 |
| Gross Profit | $16,645 | $154,419 |
| Operating Loss | $(1,129,940) | $(198,998) |
| Net Loss | $(985,521) | $(293,974) |
| Net Loss Attributable to Owners | $(962,910) | $(293,974) |
| Cash and Cash Equivalents (End of Period) | $8,795,783 | $58,370 |
| Net Cash Used in Operating Activities | $(1,435,964) | $(203,533) |
| Net Cash Provided by Financing Activities | $5,288,868 | $160,000 |
| Total Assets | $10,185,446 | $1,443,083 |
| Total Liabilities | $2,144,125 | $2,735,160 |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased by approximately 84% to $31,591 from $198,581 in Q1 2025. This was primarily due to the absence of a $116,900 milestone payment received in the prior year related to the Luliconazole licensing agreement with Sun Pharma.
- Increased Operating Expenses: Total operating expenses rose to $1.15 million from $353,417. Research and Development (R&D) expenses surged to $666,405 (from $90,268) due to scaling regulatory consulting and CMC preparation for the lead candidate VT-1953. Selling, General, and Administrative (SG&A) expenses increased to $477,575 (from $259,626) driven by professional fees related to the merger and stock-based compensation.
- Liquidity Improvement: Cash balances increased significantly to $8.8 million from $58,370. This was driven by net proceeds of approximately $5.3 million from an At-The-Market (ATM) offering in February 2026 and proceeds from the prior year's merger financing.
- Debt Conversion: All outstanding convertible notes and bridge notes were converted into equity in connection with the August 2025 merger. Consequently, interest expense dropped to $2,845 from $54,954, and fair value adjustments on debt were eliminated.
Outlook, Risks, and Contingencies
- Going Concern: Management believes current cash resources, combined with ATM proceeds, are sufficient to fund operations for at least 15 months, including the initiation of the pivotal trial for VT-1953. However, additional financing will be required to complete the trial and develop other candidates.
- Regulatory Milestones: The company plans to discuss the pivotal trial protocol for VT-1953 with the FDA in the second quarter of 2026. The VB-1953 program for acne is Phase III ready following positive Phase II results.
- Legal and Tax Contingencies:
- GST Dispute: Indian GST authorities issued a demand order of approximately $750,000 (including interest and penalties) regarding a refund claim for R&D services. Management intends to contest this and has not recorded a provision, believing the case is strong.
- Unpaid Salary: A civil court notice was received regarding deferred unpaid salary of approximately $95,000 to a past employee. This liability is already accrued on the balance sheet.
- New Licensing: In May 2026, the company entered an exclusive license agreement with Impetis Biosciences (a TATA Enterprise) for preclinical JAK inhibitor assets, with consideration limited to a 1.5% royalty on future net sales.
Investor Verification Checklist
- Cash Runway: Verify the 15-month liquidity estimate against the burn rate of $1.4M per quarter in operating cash flow.
- Revenue Concentration: Confirm the dependency on Sun Pharma for nearly 100% of pharmaceutical segment revenue and the sustainability of royalty streams without milestone payments.
- GST Liability: Monitor the status of the $750,000 Indian GST dispute and potential cash outflow if the appeal fails.
- ATM Utilization: Track the remaining capacity under the $12 million ATM facility and the dilution impact of future sales.
- Clinical Progress: Validate the timeline for FDA discussions on the VT-1953 pivotal trial protocol scheduled for Q2 2026.